Resuscitation
Another Class I recall for GE Healthcare
Federal healthcare regulators put their highest-risk Class I label on a new warning issued over GE Healthcare’s (NYSE:GE) Giraffe and Panda neonatal infant warmers and resuscitation systems.
Zoll lands FDA clearance for automated external defibrillator
Asahi Kasei (TYO:3407) subsidiary Zoll Medical won 510(k) clearance from the FDA for its fully-automated AED Plus device, which improves on the former semi-automatic model.
The new automated external defibrillator allows emergency responders to pre-program a shock instead of pushing the “shock” button.
GE Healthcare announces Class I recall of infant resuscitation kits
The FDA gave Class I status to GE Healthcare’s (NYSE:GE) recall of upgrade kits for some infant warmers over concerns that mislabeling in the kits may result in neonatal patients getting the wrong oxygen concentrations.
Patient safety: Zoll CEO makes the pledge to share data
Medical device maker Zoll Medical is among the 1st medical device companies to sign on to the patient safety and medical device data pledge proposed by Masimo (NSDQ:MASI) founder & CEO Joe Kiani this weekend.
The pledge includes promises to open up patient data gathered by medical devices to clinicians, patients and anyone else who can help improve patient care.
Asahi Kasei closes $2.3B tender for Zoll Medical
Chelmsford, Mass.-based resuscitation device maker Zoll Medical (NSDQ:ZOLL) sealed the deal with Japan’s Asahi Kasei Corp. (TYO:3407) over the weekend.
Zoll soars on news of $2.2B Asahi Kasei acquisition
Zoll Medical (NSDQ:ZOLL) is winning a lot of Wall Street love this morning on the news of a $2.21 billion cash offer from Asahi Kasei Corp. (TYO:3407).
ZOLL shares jumped 23.5% to $92.74 in morning trading today, after the Chelmsford, Mass.-based resuscitation device maker said it reached an agreement to merge with Asahi.
Zoll shares spike 23 percent on record 2011 sales and earnings | Earnings Roundup
Zoll reported record numbers in its top and bottom line for fiscal year 2011, sending its stock up 23 percent overnight.
Zoll shares were trading at $44.35 in the early afternoon today, up from last night’s $35.98 close.
The company’s 2011 sales hit a record high of $523.7 million, 18 percent higher than the $444 million posted last year.
UPDATE: Medtronic finally unloads Physio-Control
Less than a month after new CEO Omar Ishrak signaled Medtronic’s (NYSE:MDT) continued interest in selling its troublesome Physio-Control resuscitation business, the company found a buy ready to put nearly half a billion dollars on the table: private equity firm Bain Capital.
ZOLL: Reimbursement change for LifeVest would hit only 8 percent of sales
A change to the way the LifeVest is reimbursed by Medicare would affect just 8 percent of Zoll Medical Corp.’s (NSDQ:ZOLL) total sales, CEO Richard Packer told a group of analysts Wednesday.
Zoll Medical CEO discusses recent stock woes
It’s been a rough end of the summer on The Street for Zoll Medical Corp. (NSDQ:ZOLL), which has seen its share price cut nearly in half over the past six weeks.
On August 1 shares of the Chelmsford, Mass.-based resuscitation company hit an all-time high of $70.82 during midday trading on Wall Street. Investors, buoyed by the company’s strong earnings results, helped push the stock price to new heights.